No Data
No Data
Noble Financial Maintains GeoVax Labs(GOVX.US) With Buy Rating, Raises Target Price to $12
GeoVax Labs (GOVX) Receives a Buy From Noble Financial
GeoVax Labs' Promising Vaccine Trials Enhance Buy Rating Amid Robust Immune Response and Market Potential
GeoVax Labs Announces Interim Data From Phase 2 Trial of Vaccine Technology
Express News | GeoVax Labs Inc - Dsmb Recommends Continuation of Geo-Cm04S1 Vaccine Trial
Express News | GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of Covid-19 Vaccine Booster in Patients With Chronic Lymphocytic Leukemia
No Data
No Data